Clinical Trials
2 trialsNCT00710710 2022-05-04
Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT02215044 2014-08-13
Dose-finding Study of BI 2536 Administered in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer
Boehringer Ingelheim
Phase 1 Terminated